Posted by Michael Wonder on 10 Jul 2022
PBAC recommendation for amendments to COVID-19 oral treatment restrictions
10 July 2022 - The PBAC recommended changes to the PBS eligibility criteria for both molnupiravir (Lagevrio) and nirmatrelvir and ritonavir (Paxlovid), in the light of current understanding of the evidence for effectiveness and safety of these medicines, recent PBS utilisation patterns, and the changing epidemiology of COVID-19.
